Literature DB >> 12676254

A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography.

N C Hyde1, E Prvulovich, L Newman, W A Waddington, D Visvikis, P Ell.   

Abstract

OBJECTIVES: Pre-operative staging of the clinically N(0) neck in patients with oral squamous cell carcinoma is hindered by the relatively high false negative/positive rates of conventional imaging techniques. The aim of this study is to evaluate the utility of (18)F-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) and sentinel lymph node (SLN) imaging and biopsy to determine the true disease status of the loco-regional lymphatics.
METHODS: Nineteen patients with biopsy proven disease without palpable or radiological evidence of neck metastases underwent pre-operative (18)F-FDG PET and SLN imaging. All patients underwent whole-body FDG PET and a single view of the head and neck. SLN technique was performed using four peri-tumoural injections of (99m)Tc labeled albumin colloid each of 10 MBq. Dynamic and static imaging followed in the antero-posterior and lateral projections. At operation 1 ml of 2.5% Patent Blue Dye and a hand held gamma probe (Neoprobe 1500) were used in combination to identify and remove the SLN. Surgery then continued along conventional lines including a neck dissection. Histology of the resultant specimen was correlated with that of the SLN and pre-operative imaging.
RESULTS: In all patients SLN harvesting was feasible. In 15/19 patients the SLN(s) and the residual neck dissection were -ve for tumour. In 3/19 patients the SLN(s) were +ve for tumour as were other neck nodes. In 1/19 patients the SLN was -ve but another single tumour +ve node was identified in the neck. This patient occurred early in our series with a SLN close to the primary tumour. (18)F-FDG PET failed to identify nodal disease in all four patients with histologically proven lymph node metastases. The size of these nodes ranged from 12 mm x 10 mm x 3 mm to 25 mm x 15 mm x 10 mm.
CONCLUSION: SLN imaging and biopsy with probe and Patent Blue Dye guided harvest is feasible in patients with oral squamous cell carcinoma and can predict cervical nodal status. (18)F-FDG PET may be less useful. Copyright 2003 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676254     DOI: 10.1016/s1368-8375(02)00121-5

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  17 in total

Review 1.  Functional imaging in head and neck cancer.

Authors:  David I Kutler; Richard J Wong; Dennis H Kraus
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

2.  [Sentinel lymphonodectomy as a staging method for head and neck cancer. Analysis of 70 patients].

Authors:  A F Kovács; H Walendzik; N Döbert; C Menzel
Journal:  HNO       Date:  2005-06       Impact factor: 1.284

3.  Comparison of PET/CT with conventional imaging modalities (USG, CECT) in evaluation of N0 neck in head and neck squamous cell carcinoma.

Authors:  Ashutosh Chauhan; Pranjal Kulshrestha; Sanjay Kapoor; Harkirat Singh; M J Jacob; Maneel Patel; Manomoy Ganguly
Journal:  Med J Armed Forces India       Date:  2012-07-17

4.  Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer.

Authors:  Robert L Ferris; Liqiang Xi; Raja R Seethala; Jon Chan; Shaun Desai; Benjamin Hoch; William Gooding; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

5.  Positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior?

Authors:  Jolijn Brouwer; Remco de Bree; Emile F I Comans; Jonas A Castelijns; Otto S Hoekstra; C René Leemans
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-12-17       Impact factor: 2.503

6.  The role of positron emission tomography with 18F-fluorodeoxyglucose in nodal staging of clinical and radiological N₀ head and neck cancers.

Authors:  Bulent Cetin; Tamer Atasever; Umit Ozgur Akdemir; Senem Senturk; Gulnihal Tufan; Nedim Turan; Suleyman Buyukberber; Ugur Coskun; Mustafa Benekli
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-03       Impact factor: 2.503

Review 7.  Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers.

Authors:  Hubert Vermeersch; David Loose; Hamphrey Ham; Andreas Otte; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

8.  Prognostic impact of preoperative serum interleukin-6 levels in patients with early-stage oral squamous cell carcinoma, defined by sentinel node biopsy.

Authors:  Hiroyuki Goda; Masato Okamoto; Koh-Ichi Nakashiro; Satoshi Hino; Ryuichi Murase; Hiroyuki Hamakawa
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

9.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Authors:  L W T Alkureishi; Z Burak; J A Alvarez; J Ballinger; A Bilde; A J Britten; L Calabrese; C Chiesa; A Chiti; R de Bree; H W Gray; K Hunter; A F Kovacs; M Lassmann; C R Leemans; G Mamelle; M McGurk; J Mortensen; T Poli; T Shoaib; P Sloan; J A Sorensen; S J Stoeckli; J B Thomsen; G Trifiro; J Werner; G L Ross
Journal:  Ann Surg Oncol       Date:  2009-11       Impact factor: 5.344

10.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Authors:  Lee W T Alkureishi; Zeynep Burak; Julio A Alvarez; James Ballinger; Anders Bilde; Alan J Britten; Luca Calabrese; Carlo Chiesa; Arturo Chiti; Remco de Bree; Harry W Gray; Keith Hunter; Adorjan F Kovacs; Michael Lassmann; C Rene Leemans; Gerard Mamelle; Mark McGurk; Jann Mortensen; Tito Poli; Taimur Shoaib; Philip Sloan; Jens A Sorensen; Sandro J Stoeckli; Jorn B Thomsen; Giusepe Trifiro; Jochen Werner; Gary L Ross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.